Bruce Cameron Conway

U.S. SECURITIES AND EXCHANGE COMMISSION

Litigation Release No. 26370 / August 11, 2025

Securities and Exchange Commission v. Conway, No. 3:25-cv-02101 (N.D. Tex. filed Aug. 7, 2025)

SEC Charges Texas Resident with Insider Trading

On August 7, 2025, the Securities and Exchange Commission filed charges against Bruce Cameron Conway, a resident of Dallas, Texas, for insider trading in advance of the August 24, 2020 announcement that Cancer Genetics, Inc. would merge with a privately held biotechnology company.

According to the SEC’s complaint, in July 2020, in connection with an investment into a privately-held biotechnology company, Conway learned that the biotechnology company planned to merge with Cancer Genetics. The complaint further alleges Conway purchased Cancer Genetics shares in fifteen accounts belonging to him, various family members, and family-owned trusts, including purchasing shares in a personal account the same day he invested in the biotechnology company. On August 24, 2020, the merger was publicly announced, and the price of Cancer Genetics stock rose by 215 percent from the previous day’s closing price, resulting in trading profits to Conway of approximately $160,000.

The SEC’s complaint, filed in federal court in the Northern District of Texas, charges Conway with violating the antifraud provisions of Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder and seeks injunctive relief, disgorgement with prejudgment interest, and civil penalties.

The SEC’s investigation was conducted by John Dwyer and supervised by Kimberly Frederick and Nicholas Heinke, all of the SEC’s Denver Regional Office. The SEC’s litigation will be led by John Dwyer and Jodanna Haskins, under the supervision of Gregory A. Kasper. The SEC appreciates the assistance of the Financial Industry Regulatory Authority.